NCT05453812

Brief Summary

The purpose of this study is to find out the meaning of recovery after lung cancer surgery from a patient's point of view. The results of this study would help improve postoperative recovery in lung cancer patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
111

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 3, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 12, 2022

Completed
6 days until next milestone

Study Start

First participant enrolled

July 18, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2024

Completed
Last Updated

July 27, 2022

Status Verified

July 1, 2022

Enrollment Period

2 years

First QC Date

July 3, 2022

Last Update Submit

July 22, 2022

Conditions

RecoveryLung CancerSurgery

Outcome Measures

Primary Outcomes (3)

  • Importance score of each question regarding the meaning of recovery after lung cancer surgery before surgery

    Importance score of each question regarding the meaning of recovery after lung cancer surgery. The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life. Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.

    1 day before surgery

  • Importance score of each question regarding the meaning of recovery after lung cancer surgery at postoperative day 2

    Importance score of each question regarding the meaning of recovery after lung cancer surgery. The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life. Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.

    postoperative day 2

  • Importance score of each question regarding the meaning of recovery after lung cancer surgery at postoperative day 30

    Importance score of each question regarding the meaning of recovery after lung cancer surgery. The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life. Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.

    postoperative day 30 (between day 25 and 35)

Secondary Outcomes (5)

  • Recovery score (0~100 scale)

    postoperative day 2, and postoperative day 30 (between day 25 and 35)

  • Recovery score evaluated with 15-item Quality of Recovery (QoR-15K) scale

    postoperative day 2

  • Length of hospital stay (day)

    Hospital discharge, an average of 3 days

  • Length of ICU stay (day)

    ICU discharge, an average of 1 day

  • Postoperative complication

    Postoperative day 30

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients aged 19 to 80 years undergoing video-assisted thoracic surgery (VATS) lung resection for lung cancer

You may qualify if:

  • Patients aged 19 to 80 years undergoing video-assisted thoracic surgery (VATS) lung resection for lung cancer
  • Patients who can provide written consent to participate in clinical trials, understand the procedures of this clinical trial, and properly fill out patient-reported questionnaires or respond appropriately to interviews

You may not qualify if:

  • Patients who did not consent to the trial
  • Patients who have difficulty filling out questionnaires or answering interviews about the meaning of recovery
  • Patients judged to be inappropriate for this clinical trial based on the opinion of the investigator or investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, KS013, South Korea

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Hojin Lee, MD

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hojin Lee, MD

CONTACT

82-2072-2467zenerdiode03@gmail.com

Jinyoung Bae, MD

CONTACT

82-2072-2467baejy88@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Assistant Professor

Study Record Dates

First Submitted

July 3, 2022

First Posted

July 12, 2022

Study Start

July 18, 2022

Primary Completion

July 10, 2024

Study Completion

August 10, 2024

Last Updated

July 27, 2022

Record last verified: 2022-07

Locations

KR(1)